| Issue |
BIO Web Conf.
Volume 233, 2026
9th International Conference on Advances in Biosciences and Biotechnology: Emerging Innovations in Biomedical and Bioengineering Sciences (ICABB 2026)
|
|
|---|---|---|
| Article Number | 04004 | |
| Number of page(s) | 10 | |
| Section | Multi-Omics, Green Chemistry and Artificial Advancements in Biotechnology | |
| DOI | https://doi.org/10.1051/bioconf/202623304004 | |
| Published online | 23 April 2026 | |
Metabolic Vulnerability of ESKAPE Pathogens to Exogenous L-Cysteine in M9 Media: Restoring Meropenem Susceptibility
Department of Biotechnology, Jaypee Institute of Information Technology, A -10 Sec 62, Noida, India
Abstract
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) represent a critical threat to global health due to their multidrug resistance, virulence, and limited therapeutic options. The escalating failure of conventional antibiotics necessitates the identification of novel metabolic vulnerabilities that can be exploited for therapeutic intervention. Among metabolic targets, sulphur and redox metabolisms have gained increasing attention, as intracellular redox balance is essential for bacterial survival under stress and nutrient limitation. L-cysteine, a sulphur-containing amino acid, occupies a central position in bacterial metabolism as a precursor of glutathione and a regulator of cellular redox homeostasis. However, excess cysteine can induce oxidative stress through thiol autooxidation and the generation of reactive oxygen species, suggesting that cysteine availability may differentially impact bacterial viability. This study provides a comparative analysis of dosedependent, species-specific growth responses to exogenous L-cysteine across ESKAPE pathogens under nutritionally defined 0.5X M9 minimal medium conditions. Experiments were conducted over 24 hours with technical triplicates. Results demonstrate that cysteine exerts divergent effects across species. In Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enterobacter spp., exogenous cysteine significantly inhibits growth in a dose-dependent manner, while in Acinetobacter baumannii and Staphylococcus aureus, it enhances growth. The inhibitory effect of L-Cysteine on susceptible ESKAPE pathogens prompted further investigation into its potential as an antibiotic adjuvant. Meropenem (Carbapenem class antibiotic) resistant Klebsiella pneumoniae JIIT/NS72/I4 strain present in the lab was used for validating the above hypothesis. Disc diffusion assays demonstrated that while meropenem-resistant JIIT/NS72/I4 showed no zones of inhibition with meropenem alone, co-supplementation with 10 mM L-Cysteine exhibited some growth inhibition across all tested concentrations of Meropenem. Notably, Meropenem susceptibility could be restored with 10 mM L-Cysteine under nutrient-limited 0.5X M9 conditions, suggesting cysteine's adjuvant potential with antibiotic under stress conditions. These findings reveal a previously unrecognised metabolic bifurcation within the ESKAPE group, highlighting species-specific differences in sulphur assimilation, redox buffering capacity, and metabolic wiring under nutrient-restricted conditions. The study advances understanding of ESKAPE pathogen physiology and identifies cysteine-induced redox imbalance as a tractable, species-selective vulnerability with potential for pathogen-selective therapeutic intervention.
Key words: multi drug resistance / cysteine / Antibiotics / Cysteine Metabolism / Meropenem
© The Authors, published by EDP Sciences, 2026
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.

